In recent years, blood-based biomarkers have taken off in the dementia space, representing a less invasive, more cost-effective, and accessible alternative to currently accepted imaging and cerebrospinal fluid (CSF) biomarkers. The development of blood tests could be beneficial in disease screening, diagnosis, and treatment effect monitoring. Amyloid β (Aβ) and phosphorylated tau (p-tau) are used widely as diagnostic biomarkers for Alzheimer’s disease, and new modalities and assessment methods continue to be heavily investigated. With potential applications in both clinical practice and clinical trials, plasma-based measures of Aβ and tau pathology, neurodegeneration, and inflammation show particular promise, and further investigations are underway to refine these biomarkers and introduce them in a clinical setting.

In today’s episode, Stephen Salloway, MD, MS, of Warren Alpert Medical School of Brown University, Providence, RI, Nicholas Ashton, PhD, of the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Kira Trares, MSc, of the University of Heidelberg, Germany, and Joyce Van Arendonk, MSc, of the Erasmus MC University Medical Center, The Netherlands, talk on the latest advances in plasma biomarkers for Alzheimer’s disease, including recent studies and future perspectives.